^
Association details:
| Biomarker: | PMS2 1144+1G>A |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
803 - Molecular diagnosis and immunotherapy of a rare lung carcinoma patient associated with PMS2 c.1144+1G>A mutation-driven Lynch syndrome
Published date:
03/10/2021
Excerpt:
Our proband is a 62-year-old Chinese diagnosed with invasive lung adenocarcinoma...NGS panel analysis which revealed a G>A nucleotide substitution (c.1144+1G>A) located at the +1 position of intron 10 of the PMS2 gene. We also found that the proband has an oncogenic KRAS p.G13D somatic mutation...Combination chemotherapy with cisplatin (75 mg/m2), pemetrexed (500 mg/m2), and nivolumab (200 mg) was administered after surgery every 3 weeks for a total of 4 cycles to the patient. He achieved 16 months DFS.
